A number of services support the care and rehabilitation of cancer patients. These services are committed to constantly improving the treatment of patients through on-going clinical research.
|RESPECTMeso - A multicentre non-blinded randomised controlled trial to assess the impact of Regular Early SPEcialist symptom Control Treatment on quality of life in malignant Mesothelioma||Mesothelioma is a cancer of the lining around the chest wall which is caused by asbestos exposure. The UK has the highest death rate from mesothelioma in the world and will soon account for approximately 1 in 170 of all deaths in the UK. There is no cure at the moment. About a third of patients are offered chemotherapy, which can prolong how long patients live (â€˜survivalâ€™) by a few months. For many patients, doctors can only offer treatment of symptoms from the cancer, rather than treating the cancer itself. For most patients, survival is usually between 8-12 months. The purpose of this study is to examine if early specialist palliative care (SPC) involvement in mesothelioma patients can improve patientsâ€™ and carersâ€™ quality of life (QOL) during their illness.|
|CANDID - CANcer DIagnosis Decision rules Study||This study involves eight departments of the NSPCR as recruitment hubs, and three departments have additional roles (co-ordination, statistical analysis, Delphi study). If this study is successful, several external national and international collaborators will be able to apply for funds, which will have the effect of increasing the number of centres - and thus aid recruitment, improve generalisability, and increase the profile of the study. In addition, it is anticipated that the study will lead to the funding of several related studies â€“ both new cohorts and studies of impact analysis. The original application for funding proposed using a breast cancer cohort but, as suggested by the Funding Board, this has been taken out and replaced by a lung cancer cohort (see Appendix 3 for response to the Board and refereesâ€™ initial reply).|